COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
MedImmune LLC
Intima Bioscience, Inc.
A2 Biotherapeutics Inc.
Arvinas Inc.
GlaxoSmithKline
M.D. Anderson Cancer Center
Shanghai Henlius Biotech
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Takeda
National Institutes of Health Clinical Center (CC)
NantCell, Inc.
M.D. Anderson Cancer Center
Revolution Medicines, Inc.
City of Hope Medical Center
Eli Lilly and Company
Mirati Therapeutics Inc.
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A2 Biotherapeutics Inc.
Palleon Pharmaceuticals, Inc.
Turning Point Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Hoffmann-La Roche
NuCana plc
Intensity Therapeutics, Inc.
PureTech
University of Alabama at Birmingham
Case Comprehensive Cancer Center
University of Kansas Medical Center
NextCure, Inc.
M.D. Anderson Cancer Center
Essen Biotech
Coherent Biopharma (Hefei) Co., Ltd.
Chongqing Precision Biotech Co., Ltd
NantBioScience, Inc.
NantCell, Inc.
NextCure, Inc.
Augusta University
National Institutes of Health Clinical Center (CC)
University Hospital, Linkoeping
Gilead Sciences
Klus Pharma Inc.
Kineta Inc.
Eisai Inc.
Sadat City University
Chongqing Precision Biotech Co., Ltd
H. Lee Moffitt Cancer Center and Research Institute
Faron Pharmaceuticals Ltd